Vowing to spark a revolution in small molecule R&D, Vividion equips itself with an extra $82M for the final stretch to the clinic

Vividion Therapeutics has come a long way in the little more than 2 years since the company officially launched with a $45 million A round in early 2017. CEO Diego Miralles has been building his San Diego-based team and banking cash along the way, adding a $101 million deal with Celgene ? including a $97 million upfront ? for a soon-to-be-acquired biotech player with a big appetite for external discovery alliances.

Last fall they brought in a pair of experienced biotech vets ? Fred Aslan as president and head business guy and Larry Burgess to run chemistry ? and today they?re taking the wraps off a meaty $82 million B round that takes their total raise to $228 million.?

They just don?t have any drugs in the clinic. But they do have plans to rectify that in the not-too-distant future.